Skip to content

First clinical trial using embryonic stem cells announced for dry AMD treatment

Advanced Cell Technologies (ACT), a publicly listed company based in Marlborough, Maine, have announced (November 30th) the filing of an Investigational New Drug application with the FDA to use retinal pigment epithelial (RPE), cells derived human embryonic stem cells (hESC), in a Phase I/II multicentre clinical trial to treat dry age-related macular degeneration (AMD). This is only the second ever trial to use embryonic stem cells for the treatment of a human disease.